Background: Advanced heart failure (HF) is a progressive disease with high mortality and limited medical therapeutic options. Long-term mechanical circulatory support and heart transplantation remain gold-standard treatments for these patients; however, access to these therapies is limited by the advanced age and multiple comorbidities of affected patients, as well as the limited number of donor organs available. Methods: Traditional and new drugs available for the treatment of advanced HF have been researched. Results: To date, the cornerstone for the treatment of patients with advanced HF remains water restriction, intravenous loop diuretic therapy and inotropic support. However, many patients with advanced HF experience loop diuretics resistance and alternative therapeutic strategies to overcome this problem have been developed, including sequential nephron blockade or use of the hypertonic saline solution in combination with high-doses of furosemide. As classic inotropes augment myocardial oxygen consumption, new promising drugs have been introduced, including levosimendan, istaroxime and omecamtiv mecarbil. However, pharmacological agents still remain mainly short-term or palliative options in patients with acute decompensation or excluded from mechanical therapy. Conclusion: Traditional drugs, especially when administered in combination, and new medicaments represent important therapeutic options in advanced HF. However, their impact on prognosis remains unclear. Large trials are necessary to clarify their therapeutic potential and prognostic role in these fragile patients.

Butta C., Tuttolomondo A., Petrantoni R., Miceli G., Pinto A. (2020). Old and new drugs for treatment of advanced heart failure [10.2174/1381612826666191226165402].

Old and new drugs for treatment of advanced heart failure

Tuttolomondo A.
Writing – Review & Editing
;
Petrantoni R.
Investigation
;
Miceli G.
Supervision
;
Pinto A.
Supervision
2020-01-01

Abstract

Background: Advanced heart failure (HF) is a progressive disease with high mortality and limited medical therapeutic options. Long-term mechanical circulatory support and heart transplantation remain gold-standard treatments for these patients; however, access to these therapies is limited by the advanced age and multiple comorbidities of affected patients, as well as the limited number of donor organs available. Methods: Traditional and new drugs available for the treatment of advanced HF have been researched. Results: To date, the cornerstone for the treatment of patients with advanced HF remains water restriction, intravenous loop diuretic therapy and inotropic support. However, many patients with advanced HF experience loop diuretics resistance and alternative therapeutic strategies to overcome this problem have been developed, including sequential nephron blockade or use of the hypertonic saline solution in combination with high-doses of furosemide. As classic inotropes augment myocardial oxygen consumption, new promising drugs have been introduced, including levosimendan, istaroxime and omecamtiv mecarbil. However, pharmacological agents still remain mainly short-term or palliative options in patients with acute decompensation or excluded from mechanical therapy. Conclusion: Traditional drugs, especially when administered in combination, and new medicaments represent important therapeutic options in advanced HF. However, their impact on prognosis remains unclear. Large trials are necessary to clarify their therapeutic potential and prognostic role in these fragile patients.
Butta C., Tuttolomondo A., Petrantoni R., Miceli G., Pinto A. (2020). Old and new drugs for treatment of advanced heart failure [10.2174/1381612826666191226165402].
File in questo prodotto:
File Dimensione Formato  
Buttà CPD 2021 Old and new drugs for treatment of advanced heart failure.pdf

Solo gestori archvio

Tipologia: Post-print
Dimensione 461.1 kB
Formato Adobe PDF
461.1 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/489625
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 1
social impact